Tabula rasa healthcare stock price7/15/2023 ![]() These statements relate to, without limitation, the Company's financial performance and the assumptions that underlie these statements and the Company's future engagement with stockholders. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other "forward-looking" information. Such statements are identified by use of the words "believe," "will," "may," "estimate," "expect," "intend," "plans," "predict," "could," or the negative of these terms or similar expressions. Forward-looking statements give current expectations or forecasts of future events or the Company's future financial or operating performance, and include the Company's expectations regarding healthcare regulations, industry trends, available opportunities to the Company, the financial and operating performance of the Company, the impacts of the COVID-19 pandemic, and the Company's expectations for 2022 and beyond. This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Its solutions are trusted by health plans and pharmacies to help drive value-based care. TRHC's extensive clinical tele-pharmacy network improves care for patients nationwide. TRHC's proprietary technology solutions, including MedWise ®, improve patient outcomes, reduce hospitalizations, and lower healthcare costs. Tabula Rasa HealthCare (TRHC ) (NASDAQ : TRHC ) provides medication safety solutions that empower healthcare professionals and consumers to optimize medication regimens, combatting medication overload and reducing adverse drug events – the fourth leading cause of death in the US. Given the number of risk factors, uncertainties and assumptions discussed below, actual results may differ materially. The foregoing forward‐looking statements reflect our expectations as of today's date. We are confident we have the right Board and management team in place to guide TRHC forward and drive sustainable value for our stockholders as the Company continues to execute on its strategy." Tunstall continued, "We have an accomplished, diverse, and highly engaged Board with deep, relevant industry experience and business acumen, including nine directors who bring proven expertise across healthcare, finance, public service, and academia. In that spirit, the Board and management team have spoken with Indaba on multiple occasions since their initial investment in the Company in April 2022 to understand their point of view, and we expect to continue our dialogue with them and other stockholders as part of our normal investor relations process." Gordon Tunstall, TRHC's Lead Independent Director, commented on the public statements made by Indaba: "TRHC's Board of Directors and management team always strive to maintain an active dialogue with stockholders and welcome input and ideas on ways to create value and to continue to enhance our corporate governance. We continue to make important progress on both fronts as we recalibrate the business for the significant opportunities ahead in the PACE market." We also are pleased with our team's efforts to unlock value by pursuing opportunities to divest non-core assets as we sharpen our strategic focus and strengthen our balance sheet. Knowlton, PhD, TRHC's Chief Executive Officer, Chairman and Founder, said, "Our preliminary second quarter revenue performance underscores the ongoing momentum in the business as we continue to see increased demand for our core offering. The Company intends to report full unaudited financial results for the second quarter of 2022 in early August.Ĭommenting on the preliminary results, Calvin H. ![]() Preliminary unaudited revenue from continuing operations for the second quarter of 2022 is expected to be between $72 – $73 million, exceeding the prior guidance range of $66 – $69 million. ("TRHC" or the "Company") (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medications, today reported preliminary unaudited financial results for the second quarter ended Jand commented on public statements made today by Indaba Capital Management, L.P. ![]() MOORESTOWN, N.J., J/PRNewswire/ - Tabula Rasa HealthCare, Inc.
0 Comments
Leave a Reply. |